References
- Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with newer insights into classification. Clin Lymphoma Myeloma 2009;9:206–216.
- Pileri SA, Ascani S, Leoncini L, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 2002;55:162–176.
- Piccaluga PP, Agostinelli C, Gazzola A, et al. Pathobiology of Hodgkin lymphoma. Adv Hematol 2011;2011:920898.
- Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812–1826.
- Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.
- Canellos GP, Niedzwiecki D. Long term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417–1418.
- Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the childhood cancer survivor study. Blood 2011;117:1806–1816.
- Hasenclever D, Dihel V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506–1514.
- Tubiana M, Henry-Amar H, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC lymphoma group controlled clinical trials: 1964–1987. Blood 1989;73:47–56.
- Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classic Hodgkin's disease. Oncogene 2002:21:3095–3102.
- Sanchez-Aguilera A, Montalban C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662–668.
- Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classic Hodgkin lymphoma tissue uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009;113:2765–2775.
- Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010:362: 875–885.
- Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68 and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2012;31:256–262.
- Tudor CS, Distel LV, Eckhardt J, et al. B cells in Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction. Hum Pathol 2013;44:2475–2486.
- Panico L, Ronconi F, Lepore M, et al. Prognostic role of tumor associated macrophages and angiogenesis in classical Hodgkin lymphoma. Leuk Lymphoma 2013;54:2418–2425.
- Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467–1473.
- Kelley TW, Pohlman B, Elson P, et al. The ratio of FOXP3 + regulatory T cells to Granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007:128:958–965.
- Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Hematol 2002;119:122–124.
- Nelson BH. CD20 + B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010:185:4977–4982.
- Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin lymphoma. Cancer 2003;98:310–314.
- Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008;112:831–836.
- Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113:5920–5926.
- Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012;119:4129–4132.